Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $27.42 million. The enterprise value is $65.17 million.
| Market Cap | 27.42M |
| Enterprise Value | 65.17M |
Important Dates
The last earnings date was Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 4.51 million shares outstanding. The number of shares has increased by 1.91% in one year.
| Current Share Class | 4.51M |
| Shares Outstanding | 4.51M |
| Shares Change (YoY) | +1.91% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 6.45% |
| Owned by Institutions (%) | 28.68% |
| Float | 3.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.33 |
| Forward PS | 0.31 |
| PB Ratio | 2.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.73 |
| P/OCF Ratio | 9.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.33, with an EV/FCF ratio of 34.12.
| EV / Earnings | n/a |
| EV / Sales | 0.76 |
| EV / EBITDA | 8.33 |
| EV / EBIT | 29.85 |
| EV / FCF | 34.12 |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 4.39.
| Current Ratio | 1.99 |
| Quick Ratio | 0.91 |
| Debt / Equity | 4.39 |
| Debt / EBITDA | 4.33 |
| Debt / FCF | 23.10 |
| Interest Coverage | 0.38 |
Financial Efficiency
Return on equity (ROE) is -78.65% and return on invested capital (ROIC) is 4.53%.
| Return on Equity (ROE) | -78.65% |
| Return on Assets (ROA) | 1.73% |
| Return on Invested Capital (ROIC) | 4.53% |
| Return on Capital Employed (ROCE) | 4.04% |
| Weighted Average Cost of Capital (WACC) | 11.14% |
| Revenue Per Employee | $252,304 |
| Profits Per Employee | -$28,861 |
| Employee Count | 339 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 1.58 |
Taxes
| Income Tax | -115,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.12% in the last 52 weeks. The beta is 1.51, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +5.12% |
| 50-Day Moving Average | 6.00 |
| 200-Day Moving Average | 5.69 |
| Relative Strength Index (RSI) | 50.20 |
| Average Volume (20 Days) | 27,014 |
Short Selling Information
The latest short interest is 106,197, so 2.35% of the outstanding shares have been sold short.
| Short Interest | 106,197 |
| Short Previous Month | 120,933 |
| Short % of Shares Out | 2.35% |
| Short % of Float | 3.01% |
| Short Ratio (days to cover) | 3.42 |
Income Statement
In the last 12 months, HBIO had revenue of $85.53 million and -$9.78 million in losses. Loss per share was -$2.22.
| Revenue | 85.53M |
| Gross Profit | 49.97M |
| Operating Income | 2.18M |
| Pretax Income | -9.90M |
| Net Income | -9.78M |
| EBITDA | 7.82M |
| EBIT | 2.18M |
| Loss Per Share | -$2.22 |
Balance Sheet
The company has $7.10 million in cash and $44.12 million in debt, with a net cash position of -$37.02 million or -$8.21 per share.
| Cash & Cash Equivalents | 7.10M |
| Total Debt | 44.12M |
| Net Cash | -37.02M |
| Net Cash Per Share | -$8.21 |
| Equity (Book Value) | 10.05M |
| Book Value Per Share | 2.23 |
| Working Capital | 23.62M |
Cash Flow
In the last 12 months, operating cash flow was $3.08 million and capital expenditures -$1.17 million, giving a free cash flow of $1.91 million.
| Operating Cash Flow | 3.08M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 5.64M |
| Net Borrowing | 3.65M |
| Free Cash Flow | 1.91M |
| FCF Per Share | $0.42 |
Margins
Gross margin is 58.42%, with operating and profit margins of 2.55% and -11.44%.
| Gross Margin | 58.42% |
| Operating Margin | 2.55% |
| Pretax Margin | -11.57% |
| Profit Margin | -11.44% |
| EBITDA Margin | 9.15% |
| EBIT Margin | 2.55% |
| FCF Margin | 2.23% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.91% |
| Shareholder Yield | -1.91% |
| Earnings Yield | -34.76% |
| FCF Yield | 6.79% |
Analyst Forecast
The average price target for HBIO is $6.00, which is -1.32% lower than the current price. The consensus rating is "Hold".
| Price Target | $6.00 |
| Price Target Difference | -1.32% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 16, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 16, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
HBIO has an Altman Z-Score of -2.16 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.16 |
| Piotroski F-Score | 6 |